Article
Epithelial delay, pain are concerns with new NSAID
Fort Lauderdale, FL-Administration of nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) for epithelial healing and pain control resulted in delayed healing in patients who had undergone surface ablation, according to a report by Marguerite B. McDonald, MD, FACS, and William Trattler, MD, that was presented at the annual meeting of the Association for Research and Vision in Ophthalmology.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
